A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Clinical trial NCT02864290 · TERMINATED
Trial details
- NCT number
- NCT02864290
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-10
- Primary completion
- 2020-09-03
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.